nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0593	0.457	CbGbCtD
Rizatriptan—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0474	0.365	CbGbCtD
Rizatriptan—HTR1D—meninx—peripheral nervous system neoplasm	0.0439	0.148	CbGeAlD
Rizatriptan—HTR1F—trigeminal nerve—peripheral nervous system neoplasm	0.0438	0.148	CbGeAlD
Rizatriptan—HTR1B—dura mater—peripheral nervous system neoplasm	0.0417	0.141	CbGeAlD
Rizatriptan—HTR1D—dura mater—peripheral nervous system neoplasm	0.0404	0.136	CbGeAlD
Rizatriptan—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0232	0.179	CbGbCtD
Rizatriptan—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.0179	0.0605	CbGeAlD
Rizatriptan—HTR1D—trigeminal nerve—peripheral nervous system neoplasm	0.0174	0.0586	CbGeAlD
Rizatriptan—HTR1F—ganglion—peripheral nervous system neoplasm	0.0158	0.0533	CbGeAlD
Rizatriptan—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.0128	0.0431	CbGeAlD
Rizatriptan—HTR1D—cranial nerve—peripheral nervous system neoplasm	0.0124	0.0418	CbGeAlD
Rizatriptan—HTR1B—ganglion—peripheral nervous system neoplasm	0.00647	0.0218	CbGeAlD
Rizatriptan—HTR1D—ganglion—peripheral nervous system neoplasm	0.00627	0.0211	CbGeAlD
Rizatriptan—HTR1A—ganglion—peripheral nervous system neoplasm	0.00522	0.0176	CbGeAlD
Rizatriptan—MAOA—nerve—peripheral nervous system neoplasm	0.00483	0.0163	CbGeAlD
Rizatriptan—MAOA—ganglion—peripheral nervous system neoplasm	0.00477	0.0161	CbGeAlD
Rizatriptan—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.00318	0.0107	CbGeAlD
Rizatriptan—HTR1D—trigeminal ganglion—peripheral nervous system neoplasm	0.00308	0.0104	CbGeAlD
Rizatriptan—HTR1B—brainstem—peripheral nervous system neoplasm	0.00281	0.00949	CbGeAlD
Rizatriptan—HTR1D—brainstem—peripheral nervous system neoplasm	0.00272	0.00919	CbGeAlD
Rizatriptan—MAOA—trigeminal ganglion—peripheral nervous system neoplasm	0.00234	0.0079	CbGeAlD
Rizatriptan—HTR1A—brainstem—peripheral nervous system neoplasm	0.00227	0.00766	CbGeAlD
Rizatriptan—MAOA—parotid gland—peripheral nervous system neoplasm	0.00221	0.00745	CbGeAlD
Rizatriptan—MAOA—brainstem—peripheral nervous system neoplasm	0.00207	0.00699	CbGeAlD
Rizatriptan—HTR1A—cerebellum—peripheral nervous system neoplasm	0.00112	0.00377	CbGeAlD
Rizatriptan—MAOA—cerebellum—peripheral nervous system neoplasm	0.00102	0.00345	CbGeAlD
Rizatriptan—HTR1F—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.000614	0.151	CbGpPWpGaD
Rizatriptan—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000401	0.000704	CcSEcCtD
Rizatriptan—Headache—Tretinoin—peripheral nervous system neoplasm	0.0004	0.000703	CcSEcCtD
Rizatriptan—Headache—Isotretinoin—peripheral nervous system neoplasm	0.0004	0.000703	CcSEcCtD
Rizatriptan—Hypertension—Etoposide—peripheral nervous system neoplasm	0.0004	0.000702	CcSEcCtD
Rizatriptan—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000399	0.000701	CcSEcCtD
Rizatriptan—Constipation—Vincristine—peripheral nervous system neoplasm	0.000399	0.000701	CcSEcCtD
Rizatriptan—Pain—Vincristine—peripheral nervous system neoplasm	0.000399	0.000701	CcSEcCtD
Rizatriptan—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.000399	0.0007	CcSEcCtD
Rizatriptan—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000399	0.0007	CcSEcCtD
Rizatriptan—Rash—Melphalan—peripheral nervous system neoplasm	0.000398	0.000698	CcSEcCtD
Rizatriptan—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000397	0.000698	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000396	0.000695	CcSEcCtD
Rizatriptan—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000394	0.000692	CcSEcCtD
Rizatriptan—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000393	0.00069	CcSEcCtD
Rizatriptan—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000389	0.000684	CcSEcCtD
Rizatriptan—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—peripheral nervous system neoplasm	0.000388	0.0952	CbGpPWpGaD
Rizatriptan—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000388	0.000682	CcSEcCtD
Rizatriptan—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000385	0.000677	CcSEcCtD
Rizatriptan—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000385	0.000676	CcSEcCtD
Rizatriptan—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000385	0.000676	CcSEcCtD
Rizatriptan—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000385	0.000675	CcSEcCtD
Rizatriptan—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000383	0.000672	CcSEcCtD
Rizatriptan—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000383	0.000672	CcSEcCtD
Rizatriptan—Nausea—Topotecan—peripheral nervous system neoplasm	0.000383	0.000672	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000381	0.00067	CcSEcCtD
Rizatriptan—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000381	0.00067	CcSEcCtD
Rizatriptan—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000381	0.000669	CcSEcCtD
Rizatriptan—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.00038	0.000668	CcSEcCtD
Rizatriptan—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000379	0.000666	CcSEcCtD
Rizatriptan—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000379	0.000666	CcSEcCtD
Rizatriptan—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000378	0.000664	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000376	0.00066	CcSEcCtD
Rizatriptan—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000375	0.000659	CcSEcCtD
Rizatriptan—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000375	0.000659	CcSEcCtD
Rizatriptan—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000375	0.000658	CcSEcCtD
Rizatriptan—Nausea—Melphalan—peripheral nervous system neoplasm	0.000375	0.000658	CcSEcCtD
Rizatriptan—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000373	0.000654	CcSEcCtD
Rizatriptan—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000371	0.000651	CcSEcCtD
Rizatriptan—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.00037	0.00065	CcSEcCtD
Rizatriptan—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000369	0.000648	CcSEcCtD
Rizatriptan—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000369	0.000648	CcSEcCtD
Rizatriptan—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000369	0.000648	CcSEcCtD
Rizatriptan—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000368	0.000646	CcSEcCtD
Rizatriptan—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000365	0.000642	CcSEcCtD
Rizatriptan—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000363	0.000637	CcSEcCtD
Rizatriptan—Anorexia—Etoposide—peripheral nervous system neoplasm	0.00036	0.000633	CcSEcCtD
Rizatriptan—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000359	0.000631	CcSEcCtD
Rizatriptan—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000359	0.00063	CcSEcCtD
Rizatriptan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000357	0.000627	CcSEcCtD
Rizatriptan—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000357	0.000626	CcSEcCtD
Rizatriptan—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000357	0.000626	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000356	0.000625	CcSEcCtD
Rizatriptan—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000353	0.00062	CcSEcCtD
Rizatriptan—Pain—Cisplatin—peripheral nervous system neoplasm	0.000353	0.000619	CcSEcCtD
Rizatriptan—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000352	0.000618	CcSEcCtD
Rizatriptan—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000348	0.000612	CcSEcCtD
Rizatriptan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000347	0.00061	CcSEcCtD
Rizatriptan—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000609	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000346	0.000608	CcSEcCtD
Rizatriptan—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.000605	CcSEcCtD
Rizatriptan—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000344	0.000604	CcSEcCtD
Rizatriptan—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000344	0.000604	CcSEcCtD
Rizatriptan—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000343	0.000601	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.00034	0.000597	CcSEcCtD
Rizatriptan—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.00034	0.000597	CcSEcCtD
Rizatriptan—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000339	0.000596	CcSEcCtD
Rizatriptan—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000337	0.000592	CcSEcCtD
Rizatriptan—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000336	0.00059	CcSEcCtD
Rizatriptan—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000336	0.00059	CcSEcCtD
Rizatriptan—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000335	0.000588	CcSEcCtD
Rizatriptan—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000332	0.000583	CcSEcCtD
Rizatriptan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000331	0.000582	CcSEcCtD
Rizatriptan—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000329	0.000578	CcSEcCtD
Rizatriptan—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000329	0.000577	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000326	0.000573	CcSEcCtD
Rizatriptan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000326	0.000573	CcSEcCtD
Rizatriptan—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000326	0.000572	CcSEcCtD
Rizatriptan—Pain—Etoposide—peripheral nervous system neoplasm	0.000323	0.000567	CcSEcCtD
Rizatriptan—Constipation—Etoposide—peripheral nervous system neoplasm	0.000323	0.000567	CcSEcCtD
Rizatriptan—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000322	0.000566	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.000563	CcSEcCtD
Rizatriptan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00032	0.000562	CcSEcCtD
Rizatriptan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000319	0.000561	CcSEcCtD
Rizatriptan—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000318	0.000559	CcSEcCtD
Rizatriptan—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000559	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000315	0.000552	CcSEcCtD
Rizatriptan—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000313	0.00055	CcSEcCtD
Rizatriptan—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000311	0.000547	CcSEcCtD
Rizatriptan—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00031	0.000545	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000309	0.000543	CcSEcCtD
Rizatriptan—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000308	0.000542	CcSEcCtD
Rizatriptan—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000308	0.000541	CcSEcCtD
Rizatriptan—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000305	0.000536	CcSEcCtD
Rizatriptan—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000305	0.000536	CcSEcCtD
Rizatriptan—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000304	0.000534	CcSEcCtD
Rizatriptan—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000304	0.000533	CcSEcCtD
Rizatriptan—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000303	0.000533	CcSEcCtD
Rizatriptan—Urticaria—Etoposide—peripheral nervous system neoplasm	0.0003	0.000527	CcSEcCtD
Rizatriptan—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000299	0.000525	CcSEcCtD
Rizatriptan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000299	0.000525	CcSEcCtD
Rizatriptan—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000297	0.000521	CcSEcCtD
Rizatriptan—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000297	0.000521	CcSEcCtD
Rizatriptan—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000296	0.00052	CcSEcCtD
Rizatriptan—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000296	0.00052	CcSEcCtD
Rizatriptan—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000295	0.000517	CcSEcCtD
Rizatriptan—Rash—Vincristine—peripheral nervous system neoplasm	0.000294	0.000517	CcSEcCtD
Rizatriptan—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000294	0.000516	CcSEcCtD
Rizatriptan—Headache—Vincristine—peripheral nervous system neoplasm	0.000292	0.000513	CcSEcCtD
Rizatriptan—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.000509	CcSEcCtD
Rizatriptan—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000288	0.000505	CcSEcCtD
Rizatriptan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000282	0.000496	CcSEcCtD
Rizatriptan—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000281	0.000493	CcSEcCtD
Rizatriptan—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000278	0.000489	CcSEcCtD
Rizatriptan—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000278	0.000488	CcSEcCtD
Rizatriptan—Nausea—Vincristine—peripheral nervous system neoplasm	0.000277	0.000487	CcSEcCtD
Rizatriptan—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000277	0.000486	CcSEcCtD
Rizatriptan—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000274	0.000482	CcSEcCtD
Rizatriptan—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000274	0.000481	CcSEcCtD
Rizatriptan—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000271	0.000476	CcSEcCtD
Rizatriptan—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000475	CcSEcCtD
Rizatriptan—Chills—Epirubicin—peripheral nervous system neoplasm	0.000268	0.00047	CcSEcCtD
Rizatriptan—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000267	0.00047	CcSEcCtD
Rizatriptan—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000266	0.000468	CcSEcCtD
Rizatriptan—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000262	0.000461	CcSEcCtD
Rizatriptan—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000261	0.000459	CcSEcCtD
Rizatriptan—Rash—Cisplatin—peripheral nervous system neoplasm	0.00026	0.000457	CcSEcCtD
Rizatriptan—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.00026	0.000456	CcSEcCtD
Rizatriptan—Erythema—Epirubicin—peripheral nervous system neoplasm	0.00026	0.000456	CcSEcCtD
Rizatriptan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000259	0.000454	CcSEcCtD
Rizatriptan—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000257	0.000452	CcSEcCtD
Rizatriptan—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.00045	CcSEcCtD
Rizatriptan—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000256	0.000449	CcSEcCtD
Rizatriptan—Tension—Epirubicin—peripheral nervous system neoplasm	0.000255	0.000447	CcSEcCtD
Rizatriptan—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000446	CcSEcCtD
Rizatriptan—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000252	0.000443	CcSEcCtD
Rizatriptan—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.00044	CcSEcCtD
Rizatriptan—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00025	0.000439	CcSEcCtD
Rizatriptan—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.00025	0.000438	CcSEcCtD
Rizatriptan—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000435	CcSEcCtD
Rizatriptan—MAOA—Dopamine metabolism—TH—peripheral nervous system neoplasm	0.000248	0.0607	CbGpPWpGaD
Rizatriptan—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.000433	CcSEcCtD
Rizatriptan—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000245	0.00043	CcSEcCtD
Rizatriptan—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000245	0.00043	CcSEcCtD
Rizatriptan—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.000424	CcSEcCtD
Rizatriptan—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00024	0.000422	CcSEcCtD
Rizatriptan—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000422	CcSEcCtD
Rizatriptan—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000239	0.000419	CcSEcCtD
Rizatriptan—Rash—Etoposide—peripheral nervous system neoplasm	0.000238	0.000418	CcSEcCtD
Rizatriptan—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000238	0.000418	CcSEcCtD
Rizatriptan—Headache—Etoposide—peripheral nervous system neoplasm	0.000237	0.000416	CcSEcCtD
Rizatriptan—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000237	0.000416	CcSEcCtD
Rizatriptan—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000236	0.000414	CcSEcCtD
Rizatriptan—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000413	CcSEcCtD
Rizatriptan—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.00041	CcSEcCtD
Rizatriptan—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000233	0.00041	CcSEcCtD
Rizatriptan—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000233	0.000409	CcSEcCtD
Rizatriptan—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000405	CcSEcCtD
Rizatriptan—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000403	CcSEcCtD
Rizatriptan—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000401	CcSEcCtD
Rizatriptan—Cough—Epirubicin—peripheral nervous system neoplasm	0.000226	0.000398	CcSEcCtD
Rizatriptan—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000226	0.000397	CcSEcCtD
Rizatriptan—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000395	CcSEcCtD
Rizatriptan—Nausea—Etoposide—peripheral nervous system neoplasm	0.000224	0.000394	CcSEcCtD
Rizatriptan—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000394	CcSEcCtD
Rizatriptan—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000388	CcSEcCtD
Rizatriptan—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000388	CcSEcCtD
Rizatriptan—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000388	CcSEcCtD
Rizatriptan—MAOA—Biogenic Amine Synthesis—TH—peripheral nervous system neoplasm	0.000221	0.0541	CbGpPWpGaD
Rizatriptan—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000221	0.000388	CcSEcCtD
Rizatriptan—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000387	CcSEcCtD
Rizatriptan—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000218	0.000383	CcSEcCtD
Rizatriptan—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000216	0.00038	CcSEcCtD
Rizatriptan—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000216	0.000379	CcSEcCtD
Rizatriptan—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000215	0.000378	CcSEcCtD
Rizatriptan—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000375	CcSEcCtD
Rizatriptan—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000373	CcSEcCtD
Rizatriptan—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000212	0.000372	CcSEcCtD
Rizatriptan—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000212	0.000372	CcSEcCtD
Rizatriptan—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000371	CcSEcCtD
Rizatriptan—Cough—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000368	CcSEcCtD
Rizatriptan—Shock—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000366	CcSEcCtD
Rizatriptan—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.000365	CcSEcCtD
Rizatriptan—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000365	CcSEcCtD
Rizatriptan—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000364	CcSEcCtD
Rizatriptan—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000363	CcSEcCtD
Rizatriptan—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000205	0.00036	CcSEcCtD
Rizatriptan—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000359	CcSEcCtD
Rizatriptan—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000359	CcSEcCtD
Rizatriptan—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000359	CcSEcCtD
Rizatriptan—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000358	CcSEcCtD
Rizatriptan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000355	CcSEcCtD
Rizatriptan—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000202	0.000355	CcSEcCtD
Rizatriptan—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.000351	CcSEcCtD
Rizatriptan—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000347	CcSEcCtD
Rizatriptan—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.000344	CcSEcCtD
Rizatriptan—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.000344	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000339	CcSEcCtD
Rizatriptan—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000339	CcSEcCtD
Rizatriptan—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000338	CcSEcCtD
Rizatriptan—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000336	CcSEcCtD
Rizatriptan—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000336	CcSEcCtD
Rizatriptan—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000334	CcSEcCtD
Rizatriptan—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000189	0.000333	CcSEcCtD
Rizatriptan—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000332	CcSEcCtD
Rizatriptan—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000331	CcSEcCtD
Rizatriptan—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000187	0.000328	CcSEcCtD
Rizatriptan—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000186	0.000327	CcSEcCtD
Rizatriptan—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000323	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000321	CcSEcCtD
Rizatriptan—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000321	CcSEcCtD
Rizatriptan—Pain—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000318	CcSEcCtD
Rizatriptan—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000318	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000179	0.000314	CcSEcCtD
Rizatriptan—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000311	CcSEcCtD
Rizatriptan—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000309	CcSEcCtD
Rizatriptan—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000307	CcSEcCtD
Rizatriptan—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000307	CcSEcCtD
Rizatriptan—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000306	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000304	CcSEcCtD
Rizatriptan—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000303	CcSEcCtD
Rizatriptan—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000299	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.000297	CcSEcCtD
Rizatriptan—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.000297	CcSEcCtD
Rizatriptan—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000168	0.000296	CcSEcCtD
Rizatriptan—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000294	CcSEcCtD
Rizatriptan—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000294	CcSEcCtD
Rizatriptan—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000294	CcSEcCtD
Rizatriptan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000294	CcSEcCtD
Rizatriptan—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000284	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000281	CcSEcCtD
Rizatriptan—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000274	CcSEcCtD
Rizatriptan—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000273	CcSEcCtD
Rizatriptan—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000272	CcSEcCtD
Rizatriptan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000272	CcSEcCtD
Rizatriptan—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000267	CcSEcCtD
Rizatriptan—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000263	CcSEcCtD
Rizatriptan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000255	CcSEcCtD
Rizatriptan—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000254	CcSEcCtD
Rizatriptan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000247	CcSEcCtD
Rizatriptan—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000246	CcSEcCtD
Rizatriptan—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000244	CcSEcCtD
Rizatriptan—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000237	CcSEcCtD
Rizatriptan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000236	CcSEcCtD
Rizatriptan—Rash—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000235	CcSEcCtD
Rizatriptan—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000234	CcSEcCtD
Rizatriptan—Headache—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000233	CcSEcCtD
Rizatriptan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000228	CcSEcCtD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000129	0.0315	CbGpPWpGaD
Rizatriptan—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000221	CcSEcCtD
Rizatriptan—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000219	CcSEcCtD
Rizatriptan—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000217	CcSEcCtD
Rizatriptan—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000217	CcSEcCtD
Rizatriptan—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000216	CcSEcCtD
Rizatriptan—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000204	CcSEcCtD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000109	0.0268	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	7.19e-05	0.0176	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—NTS—peripheral nervous system neoplasm	5.48e-05	0.0134	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—CD55—peripheral nervous system neoplasm	5.25e-05	0.0129	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	5.01e-05	0.0123	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	4.6e-05	0.0113	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	4.5e-05	0.011	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	4.06e-05	0.00997	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	3.7e-05	0.00908	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	3.55e-05	0.00872	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—NTS—peripheral nervous system neoplasm	3.5e-05	0.00859	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	3.43e-05	0.00841	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—NTS—peripheral nervous system neoplasm	3.43e-05	0.00841	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	3.39e-05	0.00832	CbGpPWpGaD
Rizatriptan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	3.39e-05	0.00831	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CD55—peripheral nervous system neoplasm	3.36e-05	0.00824	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CD55—peripheral nervous system neoplasm	3.29e-05	0.00806	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	3.23e-05	0.00793	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	3.15e-05	0.00772	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	3.1e-05	0.00759	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	2.96e-05	0.00725	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	2.88e-05	0.00707	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—NTS—peripheral nervous system neoplasm	2.81e-05	0.00689	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	2.76e-05	0.00677	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CD55—peripheral nervous system neoplasm	2.69e-05	0.00661	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	2.61e-05	0.00641	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	2.6e-05	0.00638	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	2.55e-05	0.00624	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	2.5e-05	0.00614	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	2.46e-05	0.00604	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	2.35e-05	0.00576	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	2.35e-05	0.00575	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.28e-05	0.0056	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	2.27e-05	0.00557	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—BCHE—peripheral nervous system neoplasm	2.27e-05	0.00556	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	2.23e-05	0.00546	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	2.15e-05	0.00528	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—VIP—peripheral nervous system neoplasm	2.13e-05	0.00522	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	2.07e-05	0.00507	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	2.02e-05	0.00496	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	1.98e-05	0.00485	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.97e-05	0.00482	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	1.94e-05	0.00476	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	1.94e-05	0.00475	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—NTS—peripheral nervous system neoplasm	1.8e-05	0.00441	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	1.76e-05	0.00432	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CD55—peripheral nervous system neoplasm	1.72e-05	0.00423	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	1.7e-05	0.00416	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	1.69e-05	0.00414	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.66e-05	0.00407	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.59e-05	0.0039	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	1.57e-05	0.00386	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	1.54e-05	0.00378	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.54e-05	0.00378	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	1.54e-05	0.00378	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	1.5e-05	0.00368	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	1.48e-05	0.00362	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	1.47e-05	0.0036	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.39e-05	0.00341	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	1.38e-05	0.00338	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.38e-05	0.00338	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.36e-05	0.00334	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.35e-05	0.0033	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	1.34e-05	0.00329	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.33e-05	0.00327	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	1.29e-05	0.00315	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	1.28e-05	0.00313	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.26e-05	0.0031	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.26e-05	0.00309	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.26e-05	0.00308	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.23e-05	0.00302	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.22e-05	0.00298	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	1.17e-05	0.00288	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	1.17e-05	0.00288	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.16e-05	0.00285	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	1.13e-05	0.00278	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	1.12e-05	0.00274	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GNS—peripheral nervous system neoplasm	1.11e-05	0.00273	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.1e-05	0.00271	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—NME1—peripheral nervous system neoplasm	1.07e-05	0.00262	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.06e-05	0.0026	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	1.06e-05	0.00259	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.04e-05	0.00255	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—COX2—peripheral nervous system neoplasm	1.03e-05	0.00252	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.03e-05	0.00252	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.02e-05	0.0025	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.02e-05	0.00249	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.97e-06	0.00244	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	9.38e-06	0.0023	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	8.89e-06	0.00218	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	8.72e-06	0.00214	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	8.71e-06	0.00214	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.41e-06	0.00206	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	8.29e-06	0.00203	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	8.08e-06	0.00198	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—VIP—peripheral nervous system neoplasm	8.05e-06	0.00197	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.92e-06	0.00194	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.91e-06	0.00194	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.88e-06	0.00193	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	7.78e-06	0.00191	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.67e-06	0.00188	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	7.62e-06	0.00187	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.59e-06	0.00186	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.46e-06	0.00183	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.43e-06	0.00182	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.27e-06	0.00178	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.11e-06	0.00174	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	7.06e-06	0.00173	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	6.94e-06	0.0017	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.92e-06	0.0017	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—ENO2—peripheral nervous system neoplasm	6.75e-06	0.00166	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.63e-06	0.00163	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.52e-06	0.0016	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.02e-06	0.00148	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	6e-06	0.00147	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.8e-06	0.00142	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—BCHE—peripheral nervous system neoplasm	5.7e-06	0.0014	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.68e-06	0.00139	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.58e-06	0.00137	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.54e-06	0.00136	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.46e-06	0.00134	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.44e-06	0.00133	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—TH—peripheral nervous system neoplasm	5.36e-06	0.00132	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—HRAS—peripheral nervous system neoplasm	5.31e-06	0.0013	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.27e-06	0.00129	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.91e-06	0.0012	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.81e-06	0.00118	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.77e-06	0.00117	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.72e-06	0.00116	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.67e-06	0.00115	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.61e-06	0.00113	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.55e-06	0.00112	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.53e-06	0.00111	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.45e-06	0.00109	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GNAS—peripheral nervous system neoplasm	4.38e-06	0.00107	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—ABCB1—peripheral nervous system neoplasm	4.3e-06	0.00105	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.17e-06	0.00102	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.16e-06	0.00102	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	4.11e-06	0.00101	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.09e-06	0.001	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	3.94e-06	0.000966	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	3.79e-06	0.00093	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.66e-06	0.000898	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.58e-06	0.000879	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.56e-06	0.000873	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.39e-06	0.000832	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.38e-06	0.000828	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.28e-06	0.000805	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.25e-06	0.000798	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.11e-06	0.000763	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.98e-06	0.000731	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.95e-06	0.000724	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.9e-06	0.000711	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.89e-06	0.000709	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.84e-06	0.000696	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.73e-06	0.000669	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.54e-06	0.000623	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	2.49e-06	0.000611	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.29e-06	0.000562	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.24e-06	0.00055	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.2e-06	0.00054	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.16e-06	0.00053	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.16e-06	0.00053	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.11e-06	0.000518	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	2.1e-06	0.000516	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.1e-06	0.000515	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.09e-06	0.000511	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.08e-06	0.00051	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.06e-06	0.000504	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.04e-06	0.000499	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.01e-06	0.000492	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.99e-06	0.000489	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.98e-06	0.000485	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.91e-06	0.000468	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.87e-06	0.000458	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.76e-06	0.000432	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.74e-06	0.000428	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.71e-06	0.000419	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.71e-06	0.000419	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.62e-06	0.000398	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.61e-06	0.000396	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.61e-06	0.000395	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.59e-06	0.00039	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.58e-06	0.000389	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.57e-06	0.000384	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.55e-06	0.00038	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.42e-06	0.000349	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.33e-06	0.000327	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.31e-06	0.00032	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.3e-06	0.000319	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.28e-06	0.000313	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.25e-06	0.000306	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.21e-06	0.000297	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—AKT1—peripheral nervous system neoplasm	1.18e-06	0.00029	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.13e-06	0.000276	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.1e-06	0.00027	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.95e-07	0.000244	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.51e-07	0.000233	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.4e-07	0.000206	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	4.36e-07	0.000107	CbGpPWpGaD
